NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

This study is testing a small, refillable implant placed in the eye that continuously delivers medication for wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Researchers are comparing whether refilling the implant every 36 weeks works a…

This study is testing a one-time gene therapy injection for wet age-related macular degeneration (wet AMD), a leading cause of vision loss in older adults. The goal is to see if this single treatment can work as well as or better than the current standard of care, which requires …

This study is testing whether a new eye drop called KHK4951 can safely help control vision loss in people with 'wet' age-related macular degeneration (AMD). It will involve about 180 participants who have not recently received certain other eye injections. The main goal is to see…

This study is testing if a medication called faricimab, given as an injection into the eye, can effectively control 'wet' age-related macular degeneration (AMD) while allowing for less frequent treatments. It involves about 274 people who have not yet received treatment for this …

This study collects real-world data on how well aflibercept 8 mg eye injections work for people with vision loss from two common eye conditions: neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Researchers will follow 2500 patients who are alr…

This study looks back at existing health records to understand how doctors in Japan use aflibercept 8 mg, an injection for two common eye conditions that cause blurry vision. Researchers will analyze data from about 3,000 patients who already received this approved treatment as p…